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ABSTRACT
DEVELOPMENT OF A HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
METHOD FOR THE ANALYSIS OF NEXT-GENERATION CYANIDE ANTIDOTE,
3-MERCAPTOPYRUVATE, IN PLASMA.
ELAF ALZHRANI
2018

Although the current FDA approved cyanide antidotes (i.e., sodium nitrite,
sodium thiosulfate, and hydoxocoboalamine) are effective for treating cyanide poisoning,
each individual antidote has major limitations, including large effective dosage, delayed
onset of action, or dependence on enzymes generally confined to specific organs. To
overcome these current limitations, next-generation cyanide antidotes are being
investigated, including 3-mercaptopyruvate (3-MP). Analytical methods capable of
detecting 3-MP from plasma are essential for the development of 3-MP as a nextgeneration cyanide antidote. Although 3-MP has been analyzed by LC-MS-MS, this
instrument is not widely available. Therefore, a high performance liquid chromatography
(HPLC) method with fluorescence detection (FLD) was developed to analyze 3-MP from
swine plasma such that more labs could potentially perform the method. Sample
preparation included spiking the plasma with the internal standard (3-mercaptopropionic
acid) and reacting the 3-MP and IS with monobromobimane to prevent the characteristic
dimerization of 3-MP. The method produced a limit of detection of 0.5 nM, a large
dynamic range, and good accuracy and precision. The solid phase mixed-mode anion

exchange sample preparation protocol produced excellent selectivity for the method. The
wide availability and affordability of the instrumentation and the simple of the
implementation method presented should allow more labs to contribute to further
investigations of 3-MP as a promising cyanide antidote.

1

CHAPTER 1. INTRODUCTION
1.1.

Overall significance
Although cyanide is used as an important reagent for many industrial processes,

such as precious metal mining, synthesis of dyes, pharmaceuticals, and plastics, it is also
a highly toxic chemical that causes severe health risks which may eventually result in
death. Currently, there are three next generation cyanide antidotes that are approved by
the U.S Food and Drug Administration (FDA). However, all of them have major
limitations. Therefore, next generation cyanide antidotes are being investigated to
overcome these limitations. 3-Mercaptopyruvate is a next generation sulfur donor
therapeutic that has shown promise as cyanide antidote. Although it has been analyzed
successfully by LC-MS-MS, that instrumentation is only available in a few labs.
Therefore, there is a critical need to develop more universal, less-costly, and simple
method to analyze 3-MP from plasma.

1.2.

Project objective
The objective of this project was to develop and validate an HPLC method to

analyze 3-mercaptopyruvate from plasma.

2

1.3.

Cyanide history and discovery
1.3.1. Discovery and Identification of cyanide
Cyanide is commonly known as a toxic chemical that has been used as a poison

for thousands of years. Since the time of ancient Egypt, plants containing cyanide (e.g.,
cassava, bitter almonds, cherry laurel leaves, and peach pits) have been used as poisons.7
Romans added cherry laurel leaves (which contain CN) into a tea and used it as a method
of execution.7-8 The first description of cyanide poisoning, was by Wepfer in 1679, from
its extraction from bitter almond.9 Even though plants containing cyanide have been used
for centuries as poisons, cyanide was not identified until 1782, when Swedish pharmacist
and chemist, Carl Wilhelm Scheele, isolated cyanide from Prussian blue dye.7 In 1815,
the French chemist, Joseph Louis Guy-Lussac, provided a better understanding of
cyanides. Gay-Lussac, discovered cyanogen (a colorless, poisonous gas) which smelled
like almonds and was considerably thermally stable.9

1.4.

Cyanide Sources
1.4.1. Natural sources
The primary natural source of cyanide is from cyanogenic plants such as cassava,

sweet potatoes, limes, peaches, and almonds.10 The amount of HCN produced is different
from one plant to another. Depending on both the biosynthesis of cyanogenic glycosides
and on the existence (or absence) of its degrading enzymes.11 The first person to isolate
HCN from a plant was Scrade in 1802 (from bitter almonds and from the leaves of
peachs).11 Another natural source of cyanide is its production as a means of self-defense
by many species such as algae, bacteria, and fungi.3 Lorck was the first to show clearly
that cyanide production by bacteria is dependent on the inclusion of glycine in the growth
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medium.12 The metabolic precursor of cyanide is. Relatively 1000 species of
microorganisms and plants have been shown to produce cyanogenic compounds, also,
there have been many reported cases of livestock and human cyanide poisoning after
consumption of cyanogenic vegetation.13-14

1.4.2. Anthropogenic Sources
The annual production of cyanide, as HCN, is around 1.4 million tons
worldwide.15 Anthropogenic sources of cyanide include industrial operations, metal
extraction, fire/smoke inhalation, chemical synthesis, paint manufacturing, plastic
processing, pharmaceutical, and pesticides synthesis.15-16 There are three major processes
used to produce cyanide: 1) Andrussow, 2) Degussa, and 3) Shawinigan.17 In the
Andrussow process, HCN is produced by the reaction of ammonia and methane in the
presence of oxygen and a platinum catalyst.18 The Degussa process is similar but does not
depend on the presence of oxygen.19 In Shawinigan process, HCN is produced by the
reaction of fluidized coke particles with ammonia and propane.20
Smoke inhalation is another source of CN¯. Cyanide is produced by combustion
of nitrogen-containing compounds and inhaled as HCN.21 HCN is produced from such
common materials as plastic, wool or silk. When the combustion temperature reaches 315
ᵒC (600 ᵒF), HCN is released, and may be inhaled by the victim.22 Several reports have
shown that people who enter the hospital due to fire accidents may have been exposed to
carbon monoxide (CO) as well as cyanide (CN), and it has been recorded that the most
common source of CN poisoning in humans come from exposure to fires.22 A related
exposure is smoking, which is one of the most common sources of cyanide exposure for
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people who do not work in cyanide-related industries.3 The production of HCN from
cigarettes ranges from 10-400 µg cigarette.16
Metal extraction, especially gold, also utilizes CN as one of the most common
methods in the leaching of gold from ore. This process, called cyanidation occurs,
according to Elsner’s equation (Equation 1.1). 23 Gold is dissolved in gold containing
ores via a dilute cyanide solution in the presence of lime and oxygen.1
4Au + 8NaCN + O₂ + 2H₂ O → 4Au[Au(CN)₂ ] + 4NaOH
(1.1)
Cyanide can be removed from solution by a number of processes, such as MerrillCrowe Process.1, 5 Aside from gold mining, cyanide is also used in the extraction of
silver, copper, and zinc.5 Cyanide is also used to synthesize fibers and polymers. For
example, nitrile fibers are produced using hydrocyanation (Equation 1.2).12
RCH=CH₂ +2HCN → RCH(CN)₂ CH₃
(1.2)
In addition to fibers and polymers, CN is also used in the synthesis of
pharmaceuticals, pesticides, dyes, and pigments. Because of the extensive use of cyanide
in industry, there is an increased risk of occupational cyanide exposure.
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1.5.

Cyanide as a chemical weapon
1.5.1. Illicit use of cyanide
Cyanide delivery devices are inexpensive and easy to produce, and cyanide is

relatively easy to procure, so even small terrorist groups can use cyanide to create mass
casualties. The first use of cyanide as chemical warfare agent (CWA) was during World
War I (WWI). In late 1915 and early 1916 the French used cyanide and hydrocyanic acid
(HCN gas), but they stopped its production later because HCN gas spread quickly in open
areas, making cyanide ineffective.7 In late 1916, about the same time, French and
Austrians started using cyanogen chloride and cyanogen bromide because they are less
volatile than HCN. In humans, both convert to CN, and have the same impact on the
victims.7, 24 Japanese used cyanide against Chinese before and during World War II. In
1980s, during the Iran-Iraq War, Iran used cyanide against Syria (city of Hama)25, the
Kurds (city of Halabja)26 and Iraq.25-27 Cyanide has been used in terrorist attacks or by
individuals to poison enemies. For example, ancient Egyptians and Romans used cyanide
from cyanogenic plants, such as cherry laurel, as a poison.28 In 1978, Reverend Jim Jones
and his 900 or more of his followers drank a grape flavored drink containing cyanide.29 In
1982, Chicago Tylenol poisonings resulting from Extra-Strength Tylenol capsules which
had been laced with potassium cyanide caused a total of seven deaths.30 In 1995, in
Tokyo subway, cyanide gas-producing devices were found in the subway and railway
station restrooms during Sarin terrorist attacks.31 Also, in 2012, a Chicago lottery winner,
Urooj Khan died due to cyanide poison.32 In 2013, it was reported that Dr. Robert
Ferrante was convicted of fatally poisoning his wife with cyanide.33
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1.6.

Cyanide Toxicity
1.6.1. Mechanism of cyanide toxicity and symptoms
Cyanide is known to bind and inactivate enzymes, especially those containing

iron in the ferric state and cobalt. When cyanide binds cytochrome c oxidase, which is
located in the mitochondrial membrane, it prevents the transfer of electrons to molecular
oxygen. Therefore, the oxygen in the blood cannot be utilized toward adenosine
triphosphate (ATP) generation, which halts aerobic metabolism.34 When this occurs, the
cells first attempt to find another ATP energy source through glycolysis, leading to lactic
acidosis. This source of energy cannot be sustained, especially in the metabolically active
heart and brain and ultimately causes cellular necrosis.2, 35 A diagram of the inhibition of
cytochrome c oxidase in the mitochondrial membrane is shown in Figure 1.1. Cyanide
can affect many functions, including visual, pulmonary, cardiac, autonomic, vascular
endocrine, metabolic systems, and the central nervous system. The toxicodynamic effects
can vary based on factors such as the dose, route and speed of administration, duration of
exposure, and other physiological characteristics (age, sex, etc.).9
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Figure 1.1 Diagram of the inhibition of cytochrome c oxidase within the electron
transport chain in the mitochondrial membrane. (adapted from Ow et al.2)

It is important to note that death may occur within 5 minutes after exposure to
high doses of cyanide.9 In short and long-term cyanide exposure cases, it is reported that
some victims suffer from some chronic health problems like enlargement of the thyroid
gland, myelin deterioration, nausea, and mental health symptoms such as inability to
focus.12

Figure 1.1Commonly observed symptoms of CN exposure and their manifestation.
(adapted from Jackson et al., 2017.1)
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1.7.

Cyanide Metabolism
1.7.1. Natural cyanide metabolism pathways
Cyanide is present in human biological fluids endogenously at very low

concentrations. When cyanide is absorbed into the blood stream, it’s rapidly distributed
throughout the body and processed by multiple metabolic pathways.36 The major
metabolic pathway of cyanide (which detoxifies about 80% of cyanide dose) is
conversion of CN into thiocyanate (SCN¯) 37 using a sulfur donor and catalyzed by
rhodanese enzyme this pathway is shown in Figure 1.3. Another enzyme which catalyzes
conversion of CN into SCN¯ is 3-mercaptopyruvate sulfurtransferase (3-MST), which
yields pyruvate and SCN¯ by catalyzing the sulfuration of cyanide.4

Figure 1.2 Diagram showing the metabolic pathway of cyanide and major ways of
release. (adapted from Logue et al., 2010.3)
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One of the minor metabolic pathways is the production of 2-amino-2-thiazoline-4carboxlic acid (ATCA) by the reaction of CN with L-cystine. However, this reaction only
detoxifies around 0.10-9.19% of the CN.15 There are other metabolic pathways, but their
detoxification percentages are very small.

1.8.

Current Cyanide Antidotes
Currently, there are three US FDA approved cyanide antidotes:

hydroxocobalamin, sodium nitrite, and sodium thiosulfate. These antidotes are classified
as direct sequestering, indirect sequestering, and sulfur donation, respectively.38-39

1.8.1. Hydroxocobalamin
Hydroxocobalamin (known as vitamin B12a; Cbl) is a direct sequestering antidote
that detoxifies cyanide by direct binding. Cbl is a cobalt-containing molecule found in the
human body.40 The cobalt atom in Cbl strongly binds to the cyanide and produces
cyanocobalamin (B12) which is easily excreted from the body in the urine.41 Although Cbl
detoxifies cyanide well, it has major limitations. Cbl is a very large molecule and only
binds cyanide, so a large molar ratio is needed to sequester all the free CN, leading to
very large doses which must be administered by IV.42 Mild side effects include a high
blood pressure, low heart rate, allergic reaction, and red coloration of the skin, tears,
sweat, and urine.43
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1. 8.2. Sodium nitrite
Sodium nitrite indirectly sequesters cyanide from cytochrome c oxidase. Sodium
nitrite is primarily classified as a methemoglobin generator, it oxidizes ferrous (2+) iron
to ferric (3+) iron in hemoglobin to produce methemoglobin which has higher affinity for
CN.4, 44 Methemoglobin works as a temporary binding site for cyanide ion which
decreases free cyanide in the bloodstream.38 Recently, another alternative mechanism of
action of sodium nitrite was proposed in which nitrite converts to nitric oxide which
displaces cyanide bound to cytochrome c oxidase. After displacement, cyanide is
converted to less harmful compounds.38, 45 Although, sodium nitrite is an effective
cyanide antidote, it has some drawbacks. Sodium nitrite produces nitric oxide and
methemoglobin. Nitric oxide can cause hypotension, and methemoglobin reduces
oxygen-carrying capacity of blood. The latter can cause adverse effects for smoke
inhalation victims who may have high carboxyhemoglobin concentrations, which also
reduces blood-oxygen-carrying capacity.4 Additionally, if the production of
methemoglobin is excessive (>30%), it can pose a health risk by itself, especially for
children, causing cyanosis, fatigue, coma, and even death.38

1. 8.3. Sodium thiosulfate
Sodium thiosulfate is the only currently approved cyanide antidote that works as a
sulfur donor for the treatment of cyanide poisoning. Sodium thiosulfate eliminates
cyanide by donating a sulfur atom through sulfurtransferase enzymes as catalysts to
convert cyanide to SCN¯.46 During the conversion of cyanide to thiocyanate with sodium
thiosulfate and rhodanese, a sulfur atom is transferred from the donor to the enzyme,
producing a persulfide intermediate, and a sulfite is released in the transition. After that,
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the persulfide is transferred from the enzyme to CN converting it to thiocyanate.4
Although sodium thiosulfate detoxifies cyanide well, it has limitations. Its antidotal
activity is limited by its short biological half-life, small volume of distribution, and its
dependence on rhodanese to catalyze the sulfur transfer reaction. Rhodanese is only
found in the liver and kidneys, leaving the main locations of cyanide toxicity (the heart
and the brain) less protected. Additionally, sodium thiosulfate has a slow onset of action,
which causes slow entry into cells and mitochondria.4, 39 Due to its limitations, sodium
thiosulfate is administered in conjunction with other antidotes.

1.9.

Novel cyanide antidotes
Considering the major limitations of the current cyanide antidotes, multiple

investigations have been in progress to develop the next generation antidote for the
treatment of cyanide toxicity.4 Three next-generation cyanide antidotes have been
extensively studied and hold the most promise as novel CN antidotes: cobinamide (Cbi),
dimethyltrsulfide (DMTS), and 3-MP.

1.9.1. Cobinamide (Cbi)
Cbi is the penultimate precursor to hydroxocobalmin and is present in human
serum and bile, meaning that it is likely absorbed across intestinal epithelial cells.4 Cbi
lacks the dimethylbenzimidazole ribnucleotide tail of Cbl.4, 47 Cbi has a great affinity
towards CN binding, and it directly sequesters two CN ions.4 Several studies have
demonstrated the differences between Cbl and Cbi and the results showed that Cbi was at
least two to three times more effective than Cbl at detoxifying cyanide.4, 48 Also, Cbi has
been shown to reverse the effects of cyanide faster than Cbl.4, 8 Although Cbi detoxifies
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cyanide well, it has some disadvantages as cyanide antidote, such as large molecular
weight, large volume of administration, and it is costly.

Figure 1.3 Structure of cobinamide.4 The center cobalt atom has a great affinity
toward CN binding.
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1.9.2. Dimethyl trisulfide (DMTS)
DMTS is a sulfur-based molecule found in garlic, onion, broccoli, and similar
plants.49 DMTS converts cyanide into thiocyanate without the need of rhodanese and its
high lipophilicity permits its effective penetration of the cell membrane and the blood
brain barrier, leading to better in-vivo antidotal efficacy than thiosulfate.38, 49 Several
recent studies show that DMTS is 43 times more effective at detoxifying cyanide in the
presence of rhodanese compared to sodium thiosulfate.38, 49 Whereas, its relative efficacy
is even higher in the absence of rhodanese with 79 times greater efficacy than
thiosulfate.38, 49 Although DMTS detoxifies cyanide well, it has some limitations. DMTS
is unstable and it is hard to control the DMTS concentration under biological conditions.
It is also highly lipophilic, which limits its solubility.

1.9.3. 3-Mercaptopyruvate (3-MP)
3-MP acts as a sulfur donor to convert cyanide to thiocyanate. This reaction is
catalyzed by 3-mercaptopyruvate sulfurtransferase.4 3-MST is a more common enzyme
than rhodanese with the most important areas of high 3-MST concentrations being the
main locations of cyanide toxicity, the heart and the brain. The conversion of CN to
SCN¯ with 3-MP and 3-MST happens primarily in blood or tissue areas near blood. The
mechanism for detoxification of cyanide with 3-MP by 3-MST is shown in Figure 1.5. It
should be noted that 3-MST is distributed in both the cytosol and mitochondria.4
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Figure 1.5 Proposed catalytic mechanism for 3-mercaptopyruvate-dependent
sulfurtransfer. (a) Formation of the enzyme–substrate complex; (b) isomerization of
the Cys237 covalent disulfide intermediate to the related thiosulfoxide; (c) the
sulfane S atom is donated to cyanide, yielding the 3-cysteinyl-pyruvate adduct; (d)
and (e) nucleophilic attack on the latter covalent intermediate releases the pyruvate
analogue and frees the SseA active site. Adopted from6
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3-MP has shown to be more effective than traditional cyanide antidotes.12 It has
good stability and it can be controlled under biological conditions. Some studies have
been performed to develop a method that is able to detect 3-MP from animal plasma.
However, each of these methods has specific limitations (described in chapter 2).
Therefore, there is a critical need to develop simple, universal, and low-cost method
without the need of mass spectral detection.
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CHAPTER 2. Development of a High Performance Liquid Chromatography
Method for the Analysis of Next-generation Cyanide Antidote, 3-mercaptopyruvate
in Plasma.
2.1.

Abstract
Cyanide is a highly toxic chemical that causes severe health risks which may

eventually result in death. Although current FDA approved cyanide therapies are
effective, next generation cyanide antidotes are being investigated to overcome
limitations associated with these therapies. 3-Mercaptopyruvate (3-MP) is a next
generation sulfur donor therapeutic that has shown promise as cyanide antidote.
Analytical methods capable of detecting 3-MP in biological fluids are necessary for the
development of 3-MP as a promising antidote. Although 3-MP has been analyzed by LCMS-MS, this instrument is not widely available. Therefore, a high performance liquid
chromatography (HPLC) method with fluorescence detection was developed to analyze
3-MP from swine plasma such that more labs could potentially perform the method.
Sample preparation included spiking the plasma with an internal standard (3mercaptopropionic acid), reaction with monobromobimane to prevent the characteristic
dimerization of 3-MP, and mixed mode anion exchange solid phase extraction. The
method produced a limit of detection of 0.5 nM and a dynamic range of 0.1-10 µM. The
accuracy and precision for the method were good. The validated HPLC-FLD method was
capable of detecting 3-MP in swine plasma and can be utilized for further investigations
of 3-MP as promising cyanide antidote.
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2.2.

Introduction
Cyanide is commonly known as a toxic chemical that causes severe health risks

which may eventually result in death. Exposure to cyanide is possible through a number
of routes, including consumption of cyanogenic plants and fruits38 (e.g., cassava roots,
bitter almonds, cherry laurel leaves, peach pits), inhalation of smoke from cigarettes
and/or fires,7 industrial operations (e.g., electroplating and plastic processing),15 and from
use of cyanide as a chemical weapon (e.g. recently in Syria).5, 15 The availability of
cyanide, and its rapidly acting nature, makes it a threat to humanity.38 Currently, there are
three cyanide therapeutics that are approved by the U.S. Food and Drug Administration
(FDA): hydroxocobalamin, sodium nitrite, and sodium thiosulfate.4
Hydroxocobalamin (known as vitamin B12a; Cbl) is direct sequestering antidote
that detoxifies cyanide by directly binding. Cyanide has high affinity towards the cobalt
atom in hydroxocobalamin that allows the formation of cyanocobalamin, which resides in
the plasma and is excreted in urine.8, 41 Although Cbl detoxifies cyanide well, it has some
major limitations, including a high recommended dose of 5 g administered over 15 min
and it is very costly. Because it requires a high dose for optimum therapeutic effect,
hydroxocobalamin must be administered by IV.4 Other mild side effects include a high
blood pressure, low heart rate, allergic reaction, and red coloration of the skin, tears,
sweat, and urine.36

Sodium nitrite indirectly sequesters cyanide from cytochrome c oxidase. Sodium
nitrite is primarily classified as a methemoglobin generator, it oxidizes ferrous (2+) iron
to ferric (3+) iron in hemoglobin to produce methemoglobin which has higher affinity for
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CN.38 Methemoglobin decreases free cyanide in the bloodstream by serving as a
temporary binding site for cyanide ion.39 Recently, an alternative mechanism of action of
sodium nitrite was proposed in which nitrite converts to nitric oxide, which then displaces
cyanide bound to cytochrome c oxidase. After displacement, cyanide is converted to less
harmful compounds.38
The third class of cyanide therapeutic is sulfur donors. The only currently
approved cyanide antidote that works as a sulfur donor is sodium thiosulfate. It eliminates
cyanide by donating a sulfur atom utilizing sulfurtransferase enzymes as catalysts to
convert cyanide to SCN¯.46 During the conversion of cyanide to thiocyanate with sodium
thiosulfate and rhodanese, a sulfur atom is transferred from the donor to the enzyme,
producing a persulfide intermediate, and sulfite is released in the transition. After that, the
persulfide is transferred from the enzyme to CN, converting it to thiocyanate.5, 38
Although sodium thiosulfate detoxifies cyanide well, it has a few drawbacks. It has a
short biological half-life, which limits its antidotal activity, a small volume of
distribution, and it is dependent on rhodanese to catalyze the sulfur transfer reaction,
which is only found in high concentrations in the liver and kidneys, leaving the heart and
the brain which are the main locations of cyanide toxicity, less protected. Moreover, the
slow onset of action of sodium thiosulfate causes slow entry into cells and
mitochondria.38 Due to its limitations, sodium thiosulfate is administered in conjunction
with other antidotes.
Considering the major limitations of the current FDA approval cyanide antidotes,
several investigations have been in progress to develop the next generation of cyanide
therapeutics. One promising approach for novel cyanide antidotes is the development of a
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sulfur-donating compound that works effectively with or without rhodanese.38 The
reaction of CN with 3-mercaptopyruvate (3-MP) utilizes 3-MST which is more common
enzyme that rhodanese and it covers the heart and the brain, which are the main locations
of cyanide toxicity. 4 The conversion of CN to SCN¯ with 3-MP and 3-MST happens
primarily in blood or tissue areas near blood. The highest concentrations of 3-MST are
found in the liver and kidneys with heart, but the brain and lungs also support the
enzyme.4
Some studies have been performed to develop a method that is able to analyze 3MP from biological samples. However, each of them has specific limitations. Ogasawara
et al.50 reported an HPLC-fluoresence method for the analysis of 3-MP in mouse tissue.
The method reported is time consuming and requires high temperatures (3-MP is highly
unstable in high temperature). Other studies performed HPLC-MS-MS to analyze 3-MP
from rabbit plasma, and simultaneously determine 3-MP and Cbi by LC tandem MS.5
However, the availability of the instrumentation needed to apply this method relatively
limited. Therefore, the objective of this study was to develop a relatively affordable and
simple analytical method that produces similar analytical parameters to the methods
available using a more universal and affordable instrument, specifically HPLC.
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2.3.

Experimental
2.3.1 Reagents and standards
All solvents were HPLC grade unless otherwise noted. 3-mercaptopyruvate (3-

MP; HSCH2COCOOH), was purchased from Santa Cruz Biotechnology (Dallas, TX,
USA). Monobromobimane (MBB) was purchased from Echelon Biosciences Inc (Salt
Lake City, UT, USA). A standard solution of (MBB) (500 µM) was prepared in
deionized water and stored at 4 °C. Acetone, formic acid (reagent grade, ≥95%), and 3mercaptopropionic acid (3-MPA) were purchased from Sigma–Aldrich (St. Louis, MO,
USA). Methanol was purchased from Fisher Scientific (Pittsburgh, PA, USA). SPE Mix
mode coulmn were purchased from Waters corporation (Milford, MA, USA). Swine
plasma (EDTA anti-coagulated) was purchased from Pel-Freeze Biological (Rogers, AR,
USA) and stored at -80 °C. 3-MP calibration and QC standards were prepared from 1
mM stock solution by serial dilution with swine plasma. The internal standard solution
was prepared from a stock solution of 100 µM 3-MPA and stored at 4 °C.

2.3.2. Sample preparation
Spiked or non-spiked swine plasma (100 μL) were added to 1.5 mL microcentrifuge, along with the internal standard 3-MPA (100 µL of 50 µM). To precipitate the
protein from the plasma, 300 µL of acetone was added and the tube was vortexed. The
samples were cold-centrifuged (Thermo Scientific Legend Micro 21R centrifuge,
Waltham, MA, USA) at 8°C for 30 min at 13,100 RPM (16,500 x g). Following
centrifugation, 300 µL of the supernatant was transferred into a 4-mL glass vial and
evaporated to dryness with air. Samples were then reconstituted with 100 µL of 0.1%
TFA in deionized water. MBB (100 µL of 500 µM) was added to react with 3-MP and 3-
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MPA to both prohibit the dimerization the reaction shown in Figure 2.1 and to add a
fluorophore to 3-MP and 3-MPA. The samples were heated on a block heater (VWR
International, Radnor, PA, USA) at 70 °C for 15 min to produce a 3-MP-bimane (3MPB) and 3-MPA-bimane (3-MPAB) complex, the reaction shown in Figure 2.2. Mixedmode anion exchange (MAX; 1 cc, 30 mg from waters) solid phase extraction (SPE)
cartridges were then used to prepare the samples for the HPLC analysis. To condition the
SPE columns, 1 mL of 100% methanol was added followed by 1 mL of deionized water.
After 200 µL sample loading, 1 mL of deionized water was added to wash the column,
followed by 1 mL of 25% methanol in water. Finally, 1 mL of 100% formic acid was
added to elute 3-MPB from the column. The sample was then evaporated with air to
dryness and reconstituted with 100 µL of 0.1% TFA in deionized water. The sample was
filtered with a 0.22 µm tetrafluoropolyethylene membrane syringe filter into a 150 µL
insert housed in glass vial.
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Figure 2.1 The reaction of 3-MP in equilibrium with its dimer and MBB to form a stable 3MPB complex 5

O
O

H3C

O
O

N

CH3

H3C

N
CH3

+ H3C
HS

N

O

N

OH

H3C

S

CH2Br
O
OH

3-MPA
MBB
3-MPAB
Figure 2.2 The reaction of 3-MPA with MBB to form a stable 3-MPAB complex
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2.3.3. HPLC analysis
An Agilent HPLC coupled with a fluorescence detector was used for HPLC
analysis of 3-MPB. Separation was performed on an Eclipse XDB C18 column, with an
injection volume of 10 μL. Mobile phases were comprised of 0.1% TFA in water (Mobile
Phase A) and 0.1% TFA in methanol (Mobile Phase B). A gradient of 10% B was applied
over 10 minutes and increased to 100% B and held for 4 minutes then reduced to 10% B
over 2 minutes. The total run-time was 16 minutes with a flow rate of 0.5 mL/min and a
3-MPB retention time of 8.5 min.

2.3.4. Calibration, quantification and limit of detection

For validation of the analytical method, we generally followed the FDA
bioanalytical method validation guidelines.51 The limit of detection (LOD) was
determined by analyzing concentrations of 3-MP below the LLOQ and determining the
lowest concentration that reproducibly produced a signal-to-noise ratio (S/N) of 3. The
noise was estimated by evaluating the peak-to-peak noise of the blank over the retention
time of 3-MP. It should be noted that 3-MP is inherently present in the plasma of
mammals, making accurate assessment of the LOD difficult.5-6 The lower limit of
quantification (LLOQ) and upper limit of quantification (ULOQ) were defined using the
following inclusion criteria: 1) calibrator precision of <15% RSD, and 2) accuracy of
±100%. The initial calibration curve was prepared starting with concentrations higher
than the LOD and up to 10 µM to determine the dynamic range, with the range later
determined 0.1–10 μM. For all experiments, calibration standards and QCs were prepared
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in swine plasma. QCs (N = 5) were prepared at three different concentrations not
included in the calibration curve: 0.75 μM (low QC), 2.5 μM (medium QC) and 3.5 μM
(high QC). The internal standard was prepared daily and added to each sample,
calibration standards and QCs during sample preparation. QCs were prepared fresh each
day in quintuplicate during intra-assay (daily) and inter-assay (over three separate days,
within six calendar days) analyses and were used to calculate intra-assay and inter-assay
accuracy and precision.
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2.4.

Results and Discussion
2.4.1 HPLC-FLD analysis of 3-MP from swine plasma
3-MP reacts rapidly with itself to produce a dimer under biological conditions,

which results in poor chromatography. MBB reacts with the thiol group of 3-MP to
produces 3-MPB (Figure 2.1). Because the free thiol is essential for dimerization. The 3MPB is a single species that produces good chromatographic behavior. The sample
preparation scheme features reaction of 3-MP and 3-MPA with bimane, followed by
mixed-mode anion exchange, SPE. Figure 2.3 shows representative chromatograms of
spiked and non-spiked 3-MPB in plasma with 3-MPB eluting around 8.6 min. As shown
in Figure 2.3, the method produced an excellent selectivity with only a small co-eluting
peak which is presumably endogenous 3-MP. Figure 2.4 shows a chromatogram
illustrates the internal standard peak with the 3-MPB peak. The main advantage of the
method presented here is that it permits more affordable analysis of samples than the LCMS-MS techniques of Stutelberg et al,5, 52 and is more simple than the HPLC-FLD
technique of Ogasawara et al.50 The analysis of an individual sample lasted around 1 hr
and 20 min, including 1 hr for sample preparation and 16 min for chromatographic
analysis.

fluorescence intensity
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Figure 2.3. Representative chromatograms of 3-MP spiked (2 µM) and non-spiked swine
plasma. The 3-MPB complex retention time is around 8.6 with only a small co-eluting
peak due to endogenous 3-MP.
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Figure 2.4. Chromatogram shows the analysis of 3-MP spiked after the internal stander
addition where 3-MPB elute around 8.5 min and internal standard peak elute around 11
min.
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Figure 2.5. Chromatogram demonstrates the difference between the LOD analysis 0.5
nM and the LOQ analysis 100 nM.
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2.4.1 Limit of detection, linear range, and sensitivity
The method produced an LOD of 0.5 nM. The resulting chromatogram is shown
in Figure 2.5. In the blank, there is a small endogenous level of 3-MP coming from swine
plasma. Even considering this peak as part of the noise, the LOD was excellent
comparing to other methods. The LOD for the current method was approximately 2
orders of magnitude below the LOD from the HPLC-MS-MS methods of Stutelberg et
al.5 For Ogasawara el al, the minimum detectable level was 2 µM for 3-MP.50
The dynamic range of the method was 0.1-10 µM with a correlation coefficient
(R²) = 0.9986. The resulting plot is shown in Figure 2.6. The LLOQ and the ULOQ were
0.1 and 10 µM, respectively. It should be noted that the method did not produce a good
dynamic range with lower concentrations. A chromatogram of the LOD signal comparing
with the LLOQ is shown in Figure 2.5.

log sgnal Ratio
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y = 0.248x - 0.9483
R² = 0.9986
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Figure 2.6. Dynamic range of 0.1-10 µM 3-MP in swine plasma µM concentrations with
signal ration of 3-MP vs the internal standard.
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2.4.2 Accuracy and precision
Accuracy and precision were determined by quintuplicate analysis of the low,
medium, and high QCs (0.75, 2.5, and 7.5 µM, respectively) on three different days
(within 6 calendar days; Table 1). The accuracy and precision for the method were good.
The intra-assay accuracy ±100% and the precision was <10% RSD. The inter-assay
accuracy was ±5% and precision was <9% RSD.
Table 2.1. The accuracy and precision of 3-MP analysis in spiked swine plasma by
HPLC-FLD.
Concentration
(µM)
0.75
2.5
7.5

Intra-assay a
Accuracy
(%ACC)
±9.0
±6.2
±0.87

Intra-assay a
Precision
(%RSD)
9.17
5.63
9.74

Inter-assay b
Accuracy
(%ACC)
±15
±8.2
±5.3

Inter-assay b
Precision
(%RSD)
7.1
8.6
6.7

a
QC method validation (N = 5) for Day 1.
b
QC mean from three different days of method validation (N = 15).
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2.5. Conclusion
A simple and affordable HPLC-FLD method for the analysis of 3-MP was
developed with a very low limit of detection, wide dynamic range, and good accuracy
and precision. While Ogasawara et al50 reported an HPLC fluorescence method for the
analysis of 3-MP in mouse tissue, it was time-consuming and required high temperatures
(3-MP is highly unstable at high temperatures). Other reported methods used HPLC-MSMS, and although they produced excellent analytical parameters, the instrumentation
needed to apply this method has limited availability. The availability of the method
presented here will allow further investigations of 3-MP as a promising cyanide antidote.
27
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CHAPTER 3. CONCLUSIONS AND FUTURE WORK
5.1.

Conclusion
Due to current limitations of cyanide antidotes, including large effective dos,

delayed onset of action, or dependence on enzymes generally confined to specific organs,
there is a need to develop novel cyanide antidotes. 3-MP is promising as a novel cyanide
antidote, but previously reported analytical methods have limitations, including requiring
sophisticated instrumentation. Therefore, the HPLC method developed in this study
should aid in the development of 3-MP as next generation cyanide antidote. The HPLCFLD method developed was effective for analyzing 3-MP from plasma. The method
included simple, low-cost sample preparation, an excellent detection limit, and a large
dynamic range, while producing good accuracy and precision. Also, the internal standard
used in this method is inexpensive easy to prepare and store compared with previous
methods. Also, the instrument used is widely available and affordable, so many labs can
use this method. The extraction technique, SPE mixed-mode anion exchange, allowed
excellent selectivity for the method. While the HPLC method had advantages, it still has
some drawbacks that need to be overcome, including a long HPLC analysis time of 16
minutes, and a gap between the limit of detection and the dynamic range. Overall, the
availability of this method will allow further investigations of 3-MP as a promising
cyanide antidote.
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5.2

Future work
The method presented here has significant implications in the development of 3-

MP as next-generation cyanide antidote. Follow-on work should include overcoming the
drawbacks of the reported method and application of the method for pharmacokinetic
studies.
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